Information Provided By: 
Fly News Breaks for May 24, 2019
DVAX
May 24, 2019 | 07:53 EDT
Cowen analyst Phil Nadeau noted that Dynavax has restructured to focus on the commercialization of Heplisav and will seek strategic alternatives for the future development of its immunooncology programs, including SD-101. The analyst, whose model had no assumptions for SD-101 product revenue, said he continues to think Dynavax shares are "dramatically undervalued" given the potential of Heplisav in HBV and he also believes the company has sufficient cash to make it a success. He keeps an Outperform rating and $30 price target on Dynavax.
News For DVAX From the Last 2 Days
There are no results for your query DVAX
